|
US2016109444A1
|
|
Methods and compositions for the diagnosis of crohn's disease
|
|
CN106456549A
|
|
Methods of treating celiac disease with larazotide
|
|
US2013281384A1
|
|
Larazotide acetate compositions
|
|
AU2012203787A1
|
|
Formulations for a Tight Junction Effector
|
|
WO2009137572A2
|
|
Inhibition of gliadin peptides
|
|
WO2009137436A2
|
|
Peptide conjugates
|
|
WO2009110947A2
|
|
Compositions and methods for inhibiting cytokine production
|
|
WO2009062022A1
|
|
Methods and compositions for the diagnosis of crohn's disease
|
|
WO2009052489A2
|
|
Novel inhibitors of mammalian tight junction opening
|
|
WO2009015382A2
|
|
Novel peptides that enhance tight junction permeability
|
|
WO2009006246A1
|
|
Use of tight junction antagonists in the treatment of acute long injury and acute respiratory distress syndrome
|
|
WO2008154493A2
|
|
Novel peptides that inhibit the opening of mammalian tight junctions
|
|
WO2008154350A2
|
|
Use of tight junction agonists to suppress immune responses
|
|
WO2008150981A2
|
|
Novel short peptides that inhibit the opening of mammalian tight junctions
|
|
WO2009023311A2
|
|
Transcutaneous delivery of therapeutic agents
|
|
WO2008073627A2
|
|
Method of diagnosing and treating asthma
|
|
WO2008052185A2
|
|
Materials and methods for the treatment of celiac disease
|
|
WO2008043107A2
|
|
Use of tight junction antagonists to treat inflammatory bowel disease
|
|
TW200810773A
|
|
Use of tight junction agonists to facilitate the pulmonary delivery of therapeutic agents
|
|
TW200808339A
|
|
Formulations for a tight junction effector
|
